Previous close | 24.42 |
Open | 24.51 |
Bid | 24.22 x 100 |
Ask | 24.32 x 100 |
Day's range | 24.10 - 24.82 |
52-week range | 9.26 - 26.70 |
Volume | |
Avg. volume | 255,804 |
Market cap | 669.751M |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.13 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 34.33 |
FRIENDSWOOD, Texas, May 10, 2024--Castle awarded the "Best Overall Mental Health Solution" in 8th annual MedTech Breakthrough Awards program for IDgenetix® pharmacogenomic (PGx) test
FRIENDSWOOD, Texas, May 08, 2024--Castle announced data supporting the utility of the PRAME biomarker as a risk refinement tool when considered in the context of a DecisionDx-UM result
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.